Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Immunol Invest. 2022 Jan;51(1):51-72. doi: 10.1080/08820139.2020.1808672. Epub 2020 Oct 7.
Heart and cerebral infarctions, as two important ischemic diseases, lead to the death of tissues due to inadequate blood supply and high mortality worldwide. These statuses are started via blockage of vessels and depletion of oxygen and nutrients which affected these areas. After reperfusion and restoration of oxygen supply, more severe injury was mediated by multifaceted cascades of inflammation and oxidative stress. microRNAs (miRNAs) as the regulator of biological and pathological pathways can adjust these conditions by interaction with their targets. Also, miRNAs can be modulated by preconditioning and external agents that may improve the functional outcome after IRI. miRNAs might be considered as therapeutic approaches to improve the symptoms of patients after myocardial infarction and cerebral ischemic stroke.
心脏和脑梗死是两种重要的缺血性疾病,由于血液供应不足导致组织死亡,在全球范围内具有较高的死亡率。这些情况是通过血管阻塞以及这些区域的氧气和营养物质耗竭开始的。在再灌注和氧气供应恢复后,炎症和氧化应激的多方面级联反应介导了更严重的损伤。microRNAs(miRNAs)作为生物和病理途径的调节剂,可以通过与靶标相互作用来调节这些情况。此外,miRNAs 可以通过预处理和外部因子来调节,这可能会改善 IRI 后的功能结果。miRNAs 可能被视为改善心肌梗死后和脑缺血性中风患者症状的治疗方法。